CROI 2014: Basic science review

Topics in Antiviral Medicine

Volumn 22, Issue 2, 2014, Pages 574-578

  Stevenson, Mario ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CROI 2014; Cure; HIV; Pathogenesis; Restriction factors; Viral reservoirs

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

HIV INFECTIONS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MEDICAL RESEARCH; PHYSIOLOGY; TRENDS; VIROLOGY; VIRUS LATENCY;

ANTI-HIV AGENTS; BIOMEDICAL RESEARCH; HIV; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRUS LATENCY;

EID: 84906852164     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (4)

1. Kane M, Yadav SS, Bitzegeio J, et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature. 2013;502(7472): 563-566.
2. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692-698.
3. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15(8):893-900.
4. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretro viral therapy. Nature. 2012;487(7408): 482-485.